Search

Your search keyword '"P. I. Argyropoulou"' showing total 5 results
Start Over Author "P. I. Argyropoulou"
5 results on '"P. I. Argyropoulou"'

1. MRI measurements of the pons and cerebellum in children born preterm; associations with the severity of periventricular leukomalacia and perinatal risk factors

Author

A. Bassounas, Meropi Tzoufi, Aikaterini Drougia, P. I. Argyropoulou, S. C. Efremidis, V. Xydis, Maria I. Argyropoulou, and Styliani Andronikou

Subjects
Male, medicine.medical_specialty, Cerebellum, Leukomalacia, Periventricular/*diagnosis/etiology, Leukomalacia, Periventricular, Corpus callosum, Severity of Illness Index, Central nervous system disease, Risk Factors, Pons, Internal medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, Infant, Premature, Periventricular leukomalacia, Magnetic Resonance Imaging, Cerebral infarction, business.industry, Pons Varolii, Infant, Newborn, Infant, Gestational age, Anatomy, medicine.disease, medicine.anatomical_structure, Case-Control Studies, Cardiology, Female, Neurology (clinical), Pons/*pathology, Cardiology and Cardiovascular Medicine, business, Cerebellum/*pathology
Abstract

Our purpose was to measure the size of the pons and cerebellum in preterm babies with periventricular leukomalacia (PVL), and to study their relationship with the severity of PVL and with perinatal risk factors. We examined 33 premature children, mean gestational age 31 weeks, range 26-36 weeks with PVL on MRI, and 27 full-term controls. On MRI at 0.4-5.5 years (mean 1.4 years) we measured the area of the corpus callosum and vermis, the anteroposterior diameter of the pons and the volume of the cerebellum. The area of the corpus callosum was used as a marker of white matter loss and PVL severity. All regional brain measurements except that of the vermis were significantly lower in patients than controls: corpus callosum (mm(2)): 239.6+/-92.5 vs 434.8+/-126.8, P

Published
2003
Full Text
View/download PDF

2. The height of the pituitary in preterm infants during the first 2 years of life: an MRI study

Author

A. G. Drougia, S. C. Efremidis, Styliani Andronikou, P. I. Argyropoulou, V. Xydis, Maria I. Argyropoulou, and Dimitrios N. Kiortsis

Subjects
Male, medicine.medical_specialty, Pituitary gland, Pediatrics, Leukomalacia, Periventricular, Physiology, medicine, Humans, Radiology, Nuclear Medicine and imaging, Neuroradiology, Periventricular leukomalacia, Appropriate for gestational age, medicine.diagnostic_test, business.industry, Infant, Newborn, Gestational age, Infant, Magnetic resonance imaging, medicine.disease, Magnetic Resonance Imaging, medicine.anatomical_structure, Case-Control Studies, Pituitary Gland, Infant, Small for Gestational Age, Female, Neurology (clinical), Neurosurgery, Cardiology and Cardiovascular Medicine, business, Infant, Premature, Endocrine gland
Abstract

Pituitary secretory activity is different in premature and full-term infants. The height of the pituitary is a marker of its secretory activity. Our purpose was to use MRI to measure height of the pituitary of premature infants and to compare it with full-term controls. The height was measured on a midline sagittal T1-weighted image in 86 premature infants (gestational age 26-36.9 weeks, mean 32.3+/-2.85 weeks, corrected age 0.33-2 years, mean 0.76+/-0.42 years) and in 70 age- and sex-matched full-term controls. The children were was divided into four age groups: A:or =0.5 years; B: 0.51-1.0 year; C: 1.01-1.5 years; and D: 1.51-2.00 years. The gland was significantly (P0.01) higher in the preterm infants than in the controls (3.88+/-0.61 vs 3.31+/-0.64 mm). In the preterm group no significant difference was found between children small or appropriate for gestational age or between those with and without periventricular leukomalacia. Pituitary height by age group was: A: 3.71+/-0.57, B: 3.81+/-0.56, C: 4.09+/-0.68; and D:4.45+/-0.57 mm; statistically significant (P0.01) differences were found between groups A and D and B and D. The pituitary is thus higher in premature than in full-term controls and shows a trend to increase after the first year of corrected-age life.

Published
2003

3. Myxopapillary ependymoma of the conus medullaris with subarachnoid haemorrhage: MRI in two cases

Author

P. Gogos, I. Manavis, S. C. Efremidis, Maria I. Argyropoulou, P. I. Argyropoulou, and C. Tsampoulas

Subjects
musculoskeletal diseases, Ependymoma, Adult, Male, Pathology, medicine.medical_specialty, animal structures, Adolescent, Diagnosis, Differential, Spinal Cord Neoplasms/*complications/diagnosis, Peripheral Nervous System Neoplasms, Subarachnoid Hemorrhage/*etiology/*pathology, Conus, medicine, Humans, Radiology, Nuclear Medicine and imaging, Spinal Cord Neoplasms, Neuroradiology, medicine.diagnostic_test, biology, business.industry, Cauda equina, Magnetic resonance imaging, Anatomy, Subarachnoid Hemorrhage, medicine.disease, Spinal cord, biology.organism_classification, Magnetic Resonance Imaging, Conus medullaris, medicine.anatomical_structure, Peripheral Nervous System Neoplasms/*complications/diagnosis, Subarachnoid haemorrhage, Female, Neurology (clinical), Ependymoma/*complications/diagnosis, Cardiology and Cardiovascular Medicine, business
Abstract

Subarachnoid haemorrhage due to cauda equina tumour is rare. We report two myxopapillary ependymomas of the conus terminalis, presenting with in this way. Rims of low signal were observed at their upper and lower borders, mainly on T2-weighted images. This finding has been described in ependymomas of the cervical region but not, to our knowledge, in myxopapillary ependymomas of the conus terminalis. Neuroradiology

Published
2001

4. T(2) relaxation rate of basal ganglia and cortex in patients with beta-thalassaemia major.

Author

Z, Metafratzi, I, Argyropoulou M, N, Kiortsis D, C, Tsampoulas, N, Chaliassos, and C, Efremidis S

Abstract

In thalassaemic patients, neurophysiological disturbances have been associated with high serum ferritin levels and desferrioxamine therapy. In the presence of a magnetic field, ferritin, the main iron storage protein, induces a preferential decrease of the T(2) relaxation time. The purpose of this study was to evaluate thalassaemic patients for brain iron deposition by assessing the T(2) relaxation rate (1/T(2)) of the grey matter. 41 thalassaemic patients (age range 8.5-44 years, mean 24 years) and 58 age- and sex-matched controls were included in the study. Current serum ferritin levels were obtained. The 1/T(2) values of the cortex (motor and temporal) (mean 0.0122 ms(-1), SD 0.0004), putamen (mean 0.0137 ms(-1), SD 0.0004) and caudate nucleus (mean 0.0132 ms(-1), SD 0.0003) were higher in patients compared with the controls (mean 0.0110 ms(-1), SD 0.0004; mean 0.0120 ms(-1), SD 0.0005; mean 0.0117 ms(-1), SD 0.0003, respectively) (p<0.001 for all parameters). No statistically significant differences were found in the globus pallidus. No correlation was found between 1/T(2) and serum ferritin. The higher values of 1/T(2) in the cortex, putamen and caudate nucleus of thalassaemic patients probably reflect a higher iron deposition. The lack of differences in 1/T(2) of the globus pallidus might suggest that even in thalassaemic patients iron cannot exceed a saturation level.

Published
2001

5. Neuroendocrine Cell Carcinoma of Unknown Primary Arising in Long Standing History of Multiple Sclerosis

Author

Boussios, Stergios, Kostadima, Vasiliki, Batistatou, Anna, Tourkantonis, Ioannis, Fotopoulos, George, I. Argyropoulou, Maria, and Pavlidis, Nicholas

Abstract

Multiple sclerosis (MS) is a chronic autoimmune disease that targets myelinated axons in the central nervous system (CNS). Cancer of unknown primary site (CUP) is a well-recognised clinical disorder, accounting for 3–5% of all malignant epithelial tumors. CUP is clinically characterised as an aggressive disease with early dissemination. Studies of cancer risk in MS patients have shown inconsistent findings. An increased risk of malignancy in patients with MS has been suggested, but recently serious questions have been raised regarding this association. Use of disease-modifying therapies might contribute to an increased cancer risk in selected MS patients. The concurrence of MS and CUP is exceptionally rare. Here we describe the case of a neuroendocrine carcinoma of unknown primary diagnosed in a male patient with a nine-year history of MS. The discussion includes data from all available population-based register studies with estimates of certain malignancies in patients with MS.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results